The association of certain HIV-related oral lesions (HIV-OLs), such as oral candidosis and hairy leukoplakia, with decreased CD4 + lymphocyte counts [4, 5] and increased VLs in HIV-infected adult subjects has been clearly demonstrated in numerous studies [4, [6] [7] [8] [9] [10] [11] . In addition, a recent longitudinal study has suggested that the onset of oral candidosis and hairy leukoplakia was associated with a progressive reduction in CD4 + lymphocyte count and an abrupt increase in VL [7] . Clinical markers that may predict virological failure during HAART have not been evaluated adequately. Because oral lesions are well-established markers of HIV disease progression, we hypothesize that these markers could be useful to predict virological failure in patients receiving HAART. Clinical predictors of virological fail-ure, such as oral lesions, may help detect cases of virological failure in resource-limited settings where laboratory tests are not widely available or are too costly to be performed on a regular basis.
Thus, we decided to conduct this nested case-control study to evaluate the usefulness of HIV-OLs as clinical predictors of virological failure in a group of Mexican HIV-infected adult patients receiving HAART.
PATIENTS AND METHODS
We conducted a nested case-control study involving a cohort of 1134 HIV-infected patients treated with HAART at the AIDS Clinic of the Instituto Nacional de Ciencias Médicas y Nutrició n Salvador Zubirán in Mexico City, Mexico. Demographic (i.e., sex, age, education, and socioeconomic status) and clinical (i.e., stage of HIV infection, route of transmission, HAART regimen, CD4 + lymphocyte count, and VL) data were obtained from the database of the AIDS clinic, which contained data collected in a prospective manner from April 1997 through May 2005, as well as data from medical charts. Socioeconomic status classification was based on the ad hoc institutional system, which ranks patients for the purpose of establishing their payment ability on a scale from 1 (least able to pay) through 7 (most able to pay). Oral medicine data (i.e., history of HIV-OLs, tobacco use, and HIV-OLs at baseline and at follow-up visits) were collected from the database of the Oral Medicine and Pathology clinic at Instituto Nacional de Ciencias Médicas y Nutrició n Salvador Zubirán; the database was implemented in 1990 and prospectively evaluated all HIV-infected patients at their AIDS clinic visit. During these visits, a structured oral examination was conducted by trained personnel, including 2 of the authors (V.R.-A. and G.A.-S.). Standardized criteria for the diagnosis of HIV-OLs were followed [12] . According to the recommendations of the EC Clearinghouse criteria [12] , HIV-OLs are classified into 3 groups: those strongly associated with HIV infection; those less commonly associated with HIV infection; and those seen in, but not indicative of, HIV infection. Our study included the following oral mucosal lesions from the first group: pseudomembranous candidosis, erythematous candidosis, and oral candidosis (which is either pseudomembranous candidosis, erythematous candidosis, or both); hairy leukoplakia; periodontal disease, which involves linear gingival erythema, necrotizing ulcerative gingivitis, and necrotizing ulcerative periodontitis; Kaposi sarcoma and non-Hodgkin lymphoma. From the second group, lesions due to viral infections (e.g., infection due to herpes simplex virus), labial and intraoral lesions, and lesions associated with human papillomavirus (e.g., warty lesions) were included. From the third group (lesions seen in, but not indicative of, HIV infection), recurrent aphthous ulcers were included. Hyperplastic candidosis was also incorporated into our study.
Individuals who achieved an undetectable VL (!50 copies/ mL) after initiation of a new HAART regimen (either a first or subsequent regimen), had a baseline VL determination, and had at least 1 additional follow-up VL measurement after achieving an undetectable VL were eligible for the study. Patients who had treatment interruptions and patients who did not have the minimum number of VL measurements were excluded.
Case patients were patients who, after achieving an undetectable VL, experienced virological failure, defined as having at least 1 VL measurement of у2000 copies/mL while receiving treatment. Subjects who experienced an isolated rebound, achieving a VL of !2000 copies/mL, were considered to have experienced a VL "blip"and were not included in this analysis. Selected case patients were patients who underwent complete oral examinations, defined as 1 oral examination performed at approximately the same time as the baseline VL determination, a second oral examination performed at approximately the same time as the first undetectable VL determination, and a third oral examination performed at approximately the same time that an increased VL was observed. The follow-up period for the case patients was the period from the first undetectable VL measurement through the determination of a VL 12000 copies/mL.
Control subjects were patients who, after achieving an undetectable VL, continued to have undetectable VLs throughout follow-up. For each case patient, 2-3 control subjects were selected, matched by follow-up duration that was comparable to or longer than the duration of follow-up for the matched case patients. Complete oral examinations for control subjects were defined as 1 oral examination performed at approximately the same time as the baseline VL determination, a second oral examination performed at approximately the same time as the first undetectable VL determination, and a third oral examination performed at approximately the same time as a subsequent undetectable VL determination.
Oral examinations of case patients and control subjects were independently performed and blinded to VL data and CD4 + lymphocyte counts. Oral candidosis was confirmed by the demonstration of Candida species in cytological smear specimens stained by periodic acid-Schiff technique. The diagnosis of hairy leukoplakia was confirmed by the absence of response to antifungal therapy [12] .
HAART was defined as therapy with any combination of antiretroviral drugs that included at least 2 nucleoside reversetranscriptase inhibitors and 1 protease inhibitor or a nonnucleoside reverse-transcriptase inhibitor or that included a protease inhibitor and a nonnucleoside reverse-transcriptase inhibitor. Also, the combination of 3 nucleoside reverse-transcriptase inhibitors was considered to be HAART [2] .
A successful HAART regimen was defined as a HAART regimen administered to a patient who achieved VL suppression and attained an undetectable VL. Duration of HAART was the period from the initiation of the successful HAART regimen through the achievement of an undetectable VL.
Descriptive data for case patients and control subjects were summarized with conventional central tendency indexes. To look for possible associations between HIV-OLs or potential confounders and the development of virological failure, we calculated simple conditional logistic regression models using the matched sampling procedure. If an association was identified, multivariate conditional logistic regression models were built that included the suspected factor and confounders, such as socioeconomic status and clinical stage of HIV infection. Association results are shown as ORs and 95% CIs.
To better evaluate the potential response marker role of the diverse HIV-OLs, positive predictive values were calculated from the quotient of case patients with treatment failure who were affected by a given type of oral lesion divided by the total number of case patients and control subjects with that same type of oral lesion. Prevalence of treatment failure was determined for the underlying cohort. For the binomial distribution, 95% CIs were calculated. All analyses were performed using Stata software, version 7.0 (Stata).
RESULTS
In the present study, the target cohort consisted of 431 HIVinfected individuals; 109 (25.3%) fulfilled the definition criteria for case patients, and 322 (74.7%) fulfilled the definition criteria for control subjects (figure 1). Forty-seven case patients and 132 control subjects underwent complete oral examinations performed and formed the basis of the analysis. Three subjects who experienced VL "blips" (as defined in the Patients and Methods section) were not included in this analysis. Case patients (62 patients) and control subjects (190 patients) who did not undergo an oral examination were similar at baseline to those who were included in the study with regard to sex, age, socioeconomic status, transmission category, number of HAART regimens, median CD4 + lymphocyte counts (nadir and baseline), and baseline VL; however, among control subjects, patients who underwent complete oral examinations had a higher level of education than patients who were not included in the study ( ). Case patients and control subjects in-P ! .001 cluded in the study were more likely to have an advanced stage of HIV infection than were individuals who did not undergo complete oral examinations; the difference was statistically significant only for the control subjects ( ), not for the case P p .02 patients ( ). P p . 13 Complete oral examinations were performed within a median duration that included time before or after the VL determination; for case patients and control subjects, oral examinations were performed within a median of 30 days (interquartile range [IQR], 0-79 days) of the baseline VL measurement and within a median of 8 days (IQR, Ϫ24 to 34 days) of the first undetectable VL measurement. For case patients, a third oral examination was performed within a median of 14 days (IQR, 4-42 days) before or after the determination of an increased VL. Control subjects had a third oral examination performed within a median of 15 days (IQR, 7-33 days) before or after a subsequent undetectable VL was observed. The median period between the first undetectable VL and determination of virological failure was 360 days (IQR, 224-643 days).
Case patients and control subjects were similar with respect to demographic characteristics; individuals were predominantly male, predominantly from the middle socioeconomic level, and had a mean duration of education of 9 years. The socioeconomic status classification showed that individuals with higher socioeconomic status had a reduced risk of HAART failure, compared with individuals with lower socioeconomic status (table 1) .
With respect to clinical characteristics, most study subjects ). P p .33 Case patients and control subjects were similar with respect to history of HIV-OLs (68.1% and 58.3%, respectively; OR, 1.47; 95% CI, 0.76-2.82;
). As shown in table 2, the P p .25 most common HIV-OLs for all visits were oral candidosis (predominantly the erythematous type), hairy leukoplakia, and recurrent oral ulcers; however, other oral lesions, such as those caused by viral infections (e.g., infections due to herpes simplex virus and human papillomavirus), periodontal disease (e.g., linear gingival erythema and necrotizing ulcerative gingivitis), and hyperplastic candidosis (in 1 case patient) were also identified. In addition, no associations were found between HIVOLs and the risk of virological failure at baseline (OR, 0.95; 95% CI, 0.50-1.84; ) or at the first visit after an un-P p .89 detectable VL was achieved (OR, 1.39; 95% CI, 0.57-3.38;
). Median CD4 + lymphocyte counts were similar for P p .46 case patients and control subjects at the first visit after an undetectable VL was achieved (220 cell/mm 3 and 252.5 cell/ mm 3 , respectively); the difference was not statistically significant ( ) . P p . 15 In contrast, at the visit at which virological failure was determined, patients with HIV-OLs showed a higher risk for HAART failure (OR, 14.5; 95% CI, 4.2-49.9; ) than did P ! .001 those without oral lesions (table 2). The OR for HAART failure in the patients who developed oral candidosis was 26.2 (95% CI, 3.3-205.9;
). In addition, the rate of treatment P p .002 with antifungal drugs was higher among case patients (19.1%) Assuming that the prevalence of virological failure in our cohort was 26.3%, the positive predictive values associated with the most common HIV-OLs are displayed in table 4. The presence of HIV-OLs after an undetectable VL was achieved was associated with a significant increase in the predicted virological failure rate, from 26.3% to 80%.
The results for HIV-OLs and oral candidosis are remarkable, given that the lower limits of the 95% CIs clearly exclude the a priori probability of virological failure of 26.3%. On the other hand, the 95% CIs for hairy leukoplakia and recurrent oral ulcers are quite wide, which means that, at least on the basis of present results, they are not clear, strong predictors of virological failure.
DISCUSSION
Even though there is strong evidence that HAART significantly reduces the prevalence of oral manifestations of HIV infection [4, 8, [13] [14] [15] [16] and a large amount of data related to the use of HIV-OLs as clinical markers of disease progression [4, [17] [18] [19] , studies evaluating the use of HIV-OLs as markers of virological failure during HAART are limited. This is, to our knowledge, ). P p .002
Moreover, the positive predictive values for the ability of HIV-OLs and oral candidosis to identify patients who experienced virological failure while receiving HAART was high in the present study (80% and 83%, respectively), compared with a previous report [20] in which oral candidosis was associated with a positive predictive value of 52.8% at baseline and 41.7% after 6 months of follow-up. Also, the presence of concurrent lesions (oral candidosis and hairy leukoplakia) has been reported to be associated with a positive predictive value of 60% for a VL у20,000 copies/mL [21] .
Two previous studies have attempted to evaluate the association of HIV-OLs with immunological and virological failure [20, 22] . A cross-sectional study involving 151 Spanish patients with HIV infection and/or AIDS who were receiving HAART showed that only the presence of oral candidosis was related to immunological failure [22] . In addition, a prospective study involving 124 Brazilian patients with HIV infection and/or AIDS who were receiving HAART demonstrated that oral candidosis was associated with a positive predictive value of 66.7% for the outcome of CD4 + lymphocyte count !200 cells/mm 3 and 41.7% for an outcome of VL у20,000 copies/mL [20] ; in contrast, hairy leukoplakia was associated with moderate positive predictive values for both measures. In our study, after effective HAART, both groups of patients showed a marked reduction in the prevalence of HIV-OLs (from 42.5% to 21.3% for case patients and from 43.9% to 17.4% for control subjects) as a result of the immune reconstitution achieved after a median duration of HAART (case patients, 133 days; control subjects, 183 days). Similar findings have been reported in numerous studies, such as a previous study from our group that showed a decrease of 50% in HIVOLs in patients receiving HAART [15] ; other studies have shown reductions of 56% in the United States [16] , 46% in Spain [23] , and 24% in the United Kingdom [24] .
The design of this nested case-control study allowed us to evaluate how, in patients with HIV infection who are receiving HAART, HIV-OLs are associated with the onset of virological failure. This research design combines the advantages of a prospective cohort study [25] [26] [27] in which information was obtained prospectively from 1997 through 2005 with those of the so-called case-control design, resulting in a higher efficiency in identifying the impact of a feature or exposure.
Also, it is important to highlight that, in our cohort, virological failure, as defined in Patients and Methods, was meticulously distinguished from other causes of increased VL, such as HAART interruptions associated with toxicity. In addition, it is relevant to emphasize that oral examinations were performed independently and were performed by health care personnel who were blinded to VL measurements and CD4 + lymphocyte counts.
A limitation of the study was that, from the original cohort of 1134 HIV-infected patients, a significant number (529 patients; 46.6%) did not have complete VL determinations. In addition, only 179 (41.5%) of the 431 individuals in the target cohort had complete oral examinations performed. Considering the high number of patients with inadequate follow-up data, we performed a comparison between enrolled and nonenrolled patients; as a result, we found that both groups were similar, except in terms of educational background and severity of disease. Because schooling was better and disease more severe among patients who were enrolled in the study, we conclude that these features may be markers of a better compliance with medical (including oral) care. However, this bias did not seem to affect the main conclusion of the study, because these variables are not related to the main outcome (i.e., virological failure).
Our results suggest that oral candidosis may be considered to be a good clinical marker of virological failure in HIV- infected patients receiving HAART, which agrees with the findings of other authors, who have demonstrated that oral candidosis is a better predictor of virological failure than hairy leukoplakia [20, 28] . According to Flint et al. [13] , oropharyngeal candidosis fulfills 3 of the criteria for a useful marker of HIV disease progression following HAART failure: the lesion is not sex specific, it is an early sign of HIV infection in the erythematous form, and its prevalence correlates to VL.
Various studies have also demonstrated a strong correlation between high VL and oral candidosis [9, 28, 29] , and others have found a significant relationship between increased VL and both oral candidosis and hairy leukoplakia [7, 8, 11, 21, [30] [31] [32] [33] [34] .
Miziara and Weber [20] have found a slight association between hairy leukoplakia and virological failure in patients receiving HAART. Moreover, the presence of hairy leukoplakia has been associated with high and medium VLs [35, 36] . In contrast, Gaitan-Cepeda et al. [22] have suggested that hairy leukoplakia should not be considered to be a predictive marker of virological failure, because no relationship was found between virologic failure and the presence of hairy leukoplakia in their investigation. To determine the relevance of hairy leukoplakia as a clinical predictor for virological failure in our study, a larger number of patients would have been necessary.
HIV-OLs have demonstrated usefulness as indicators of disease progression and as a tool for monitoring HIV infection in conjunction with CD4 + lymphocyte count and plasma VL. Our study proposes that oral lesions, especially oral candidosis, may be considered to be clinical markers of virological failure in HIV-infected patients receiving HAART. The onset of HIVOLs, particularly oral candidosis, should alert the clinician to confirm virological failure with the appropriate laboratory testing. Clinical evaluation should not be a substitute for periodic VL measurements; however, it could be an additional tool for the clinician, especially in resource-limited settings, where VL assays may not be widely available.
